Anaplastic Astrocytoma Clinical Trials 2024

What are the top hospitals conducting anaplastic astrocytoma research?

When it comes to cutting-edge clinical trials in the battle against anaplastic astrocytoma, several prestigious hospitals are leading the way. In Chicago, Northwestern University is making strides with three active trials focused on this complex brain tumor and has already completed eleven such studies since their first recorded trial in 2004. Meanwhile, Massachusetts General Hospital in Boston stands shoulder to shoulder with three ongoing anaplastic astrocytoma trials and a history of ten previous investigations that date back to their inaugural trial in 2002.

Notably, Memorial Sloan Kettering Cancer Center located in New york City also dedicates itself to advancing knowledge about this particular brain cancer type. They currently have three active anaplastic astrocytoma trials underway while having conducted twenty-two comprehensive studies over time since initiating research on this condition back in 2002.

Another renowned institution at the forefront of medical innovation is MD Anderson Cancer Center situated Houston. With three ongoing clinical trials for anaplastic astrocytoma patients and a track record of seven previously achieved studies dating back to 2001; they continue striving forward towards understanding better ways of combating this devastating disease.

Lastly, but certainly not least important is Dana Farber Cancer Institute based out of Boston as well where efforts are being made through similar measures like conducting relevant tests employing participants who presently count up-to-three subjects & contributing additional advancements from nine such experiments which they’ve successfully accomplished so far starting from year=2005 onwards

These esteemed hospitals represent hope for those affected by anaplastic astrocytoma—a formidably challenging brain tumor—and demonstrate unwavering commitment within different regions across America’s healthcare landscape. By leveraging state-of-the-art therapies and innovative approaches derived from these extensive clinical trials, researchers aim not just at extending survival rates but ultimately improving quality of life for individuals battling against all odds.

Which are the best cities for anaplastic astrocytoma clinical trials?

When it comes to anaplastic astrocytoma clinical trials, several cities emerge as leading centers for research and innovation. Boston, Massachusetts takes the lead with 16 active trials investigating treatments like Vorasidenib, Eflornithine, and dabrafenib. Chicago, Illinois follows closely behind with 5 ongoing studies exploring interventions such as Specialized tumor board recommendation and Mycophenolate Mofetil. Similarly, New york City and Houston both boast 5 active trials focusing on treatments like dabrafenib and rQNestin. Finally, Los Angeles rounds out the list with 4 active trials examining options like Eflornithine. These cities provide individuals diagnosed with anaplastic astrocytoma access to cutting-edge clinical trials that offer hope for improved treatment outcomes in this challenging condition.

Which are the top treatments for anaplastic astrocytoma being explored in clinical trials?

Clinical trials are actively exploring several potential treatments for anaplastic astrocytoma. Among them is craniotomy, a surgical procedure currently being tested in one active trial dedicated to this specific brain tumor type. Another promising avenue is retifanlimab, a novel drug that has caught the attention of researchers and is also being evaluated in one ongoing trial. Additionally, dabrafenib, a medication initially listed in 2019, shows promise as it undergoes investigation through its involvement in one active clinical trial for anaplastic astrocytoma. These advancements offer hope as we continue to search for effective treatments against this challenging disease.

What are the most recent clinical trials for anaplastic astrocytoma?

Recent clinical trials have brought new hope to individuals with anaplastic astrocytoma, a challenging form of brain cancer. Among these trials is the investigation of low-dose OKN-007 administered twice daily, which has shown promise in early-phase studies. Additionally, the randomized perioperative phase trial focuses on evaluating the efficacy of vorasidenib as a standalone treatment for anaplastic astrocytoma patients. Another intriguing avenue involves utilizing Ad5-yCD/mutTKSR39rep-ADP adenovirus combined with fSRS therapy to target this aggressive cancer subtype. Furthermore, ongoing research explores the potential benefits of retifanlimab and mycophenolate mofetil in managing anaplastic astrocytoma. These innovative approaches hold great potential in improving outcomes for those affected by this complex disease.

What anaplastic astrocytoma clinical trials were recently completed?

Several clinical trials for anaplastic astrocytoma have recently concluded, representing significant progress in the quest for effective treatments. In May 2021, Washington University School of Medicine completed a trial examining the potential of Tadalafil in combating this aggressive form of brain cancer. Furthermore, the National Cancer Institute finished their investigation into LB-100 in January 2019 and Children's Hospital Medical Center, Cincinnati wrapped up their ribociclib trial back in November 2017. Northwestern University also contributed to these efforts with a study involving neural stem cells loaded with an oncolytic adenovirus that was completed in April 2017. Finally, Macarena De La Fuente, MD conducted a Dendritic Cell Vaccine trial which reached completion in August 2013. These endeavors underline the ongoing commitment to improve outcomes for individuals affected by anaplastic astrocytoma through innovative research and development.